L Ratiani^1,2, V Shoshiashvili^1,2*, E Vashakidze^1,2, M Rurua^1,2, E Pachkoria^1,2, E khuchua¹, L Gabunia^1,2 and K Machavariani^1,2

¹First University Clinic of Tbilisi State Medical University, Georgia
²Tbilisi State Medical University, Georgia

*Corresponding Author: V Shoshiashvili, First University Clinic of Tbilisi State Medical University, Georgia.

Received: July 16, 2021; Published: September 08, 2021

Abstract

  Coronavirus disease-2019 (COVID-19) caused by coronavirus 2 (SARS-CoV-2) infection is a global health problem; Severe COVID-19 can lead to multi-organ failure and may be associated with high mortality. The incidence and outcomes of COVID-19 in immunocompromised patients are a matter of debate, clinical presentation and management of liver injury in liver transplant patients with COVID -19 is unclear and may be an increasing challenge for the transplant centers. This is a Case report from Georgia that presents a case of COVID-19 in a patient with a liver transplant. Due to Corticosteroids and Antibiotic therapy, in parallel with continuing immunosuppressive drug full recovery was achieved. His maintenance immunosuppressive therapy includes calcineurin inhibitor (Cyclosporine) 75 mg BID, which was not ceased.

Keywords: COVID-19; Liver Transplantation; Immunosuppressants; Management

References

1. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
2. Clinical Management of COVID-19: Interim Guidance, 27 May 2020. World Health Organization (2020).
3. https://stopcov.ge/
4. de Bruin S., et al. “Clinical features and prognostic factors in Covid-19: A prospective cohort study”. Lancet 67 (2021): 103378.
5. D’Antiga L. “Coronaviruses and immunosuppressed patients. The facts during the third epidemic”. Liver Transplantation 26 (2020): 832-834.
6. Zhang C., et al. “Liver injury in COVID-19: management and challenges”. Lancet Gastroenterology and Hepatology 5 (2020): 428.
7. Adam R., et al. “Evolution of indications and results of liver transplantation in Europe. A report from the European”. (2012): 688.
8. Van Doremalen N., et al. “Aerosol and surface stability of SARS-COV-2 as compared with SARS-COV- 1”. The New England Journal of Medicine 382 (2020): 1564-1567.
9. D’Antiga L. “Coronaviruses and immunosuppressed patients. The facts during the third epidemic”. Liver Transplantation (2020).
10. Bhoori S., et al. “COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy”. Lancet Gastroenterology and Hepatology6 (2020): 532-533.
11. Liu B., et al. “Successful treatment of severe COVID- 19 pneumonia in a liver transplant recipient”. American Journal of Transplantation 7 (2020): 1891-1895.
12. Jordi Colmenero., et al. “Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients”. Journal of Hepatology1 (2021): 148-155.
13. Mehta P., et al. “COVID-19: consider cytokine storm syndromes and immunosuppression”. Lancet10229 (2020): 1033-1034.
14. https://www.jhsph.edu/news/news-releases/2021/covid-19-outcomes-for-patients-on- immunosuppressive-drugs-on-par-with-non-immunosuppressed-patients.html

Citation

Citation: V Shoshiashvili., et al. “COVID 19 in Liver Transplant Patient - Case Report”.Acta Scientific Medical Sciences 5.10 (2021): 34-37.

Copyright

Copyright: © 2021 V Shoshiashvili., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.